title: Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: María J
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: José L
authors.initials: JL
authors.lastname: Casado
authors.forename: Jesús
authors.initials: J
authors.lastname: Fortún
authors.forename: Rafael
authors.initials: R
authors.lastname: Bárcena
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Santos
authors.initials: S
authors.lastname: Del Campo
authors.forename: Carmen
authors.initials: C
authors.lastname: Gutiérrez
authors.forename: Oscar
authors.initials: O
authors.lastname: Pastor
authors.forename: Javier
authors.initials: J
authors.lastname: Nuño
authors.forename: Ana
authors.initials: A
authors.lastname: Fernandez
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000379:methods*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012367:RNA, Viral / Q000378:metabolism; D000068898:Raltegravir Potassium; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D007166:Immunosuppressive Agents; D011760:Pyrrolidinones; D012367:RNA, Viral; D000068898:Raltegravir Potassium